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ABSTRACT
OBJECTIVE AND SUBJECTIVE INFLUENCES ON COGNITIVE PERFORMANCE
IN ADOLESCENTS WITH TYPE 1 DIABETES
Natalie E. Benjamin, B.A.
Marquette University, 2017
Type 1 diabetes mellitus (T1DM) is an increasingly common chronic illness in
children and adolescents that can result in short- and long-term health complications.
Disease management can be a particular challenge for adolescents seeking autonomy
from caregivers. Recently, there has been a significant increase in adolescents’ use of
diabetes-related technology to aid in blood glucose (BG) management and insulin
administration. Individuals with T1DM also experience symptoms related to their BG
levels, and these symptoms can serve as indicators of out-of-range BG levels and guide
management decisions. Although research shows that diabetes-related health factors can
affect cognitive functioning, no existing research has explored the relationship between
cognitive performance and immediate symptomatology at the time of testing. The present
study examined the similarities and differences between objective and subjective
diabetes-related variables and their respective relationships to cognitive performance.
This study also explored the use of diabetes technology in this population, and
adolescents’ ability to accurately estimate their current BG levels.
Fifty-five adolescents (ages 13-17) diagnosed with T1DM completed the study
during a 10-day diabetes camp session. Participants completed symptom inventories and
estimated their BG level before checking it with a meter. They also completed two
cognitive assessments (Symbol Digit Modalities Test, or SDMT, and D-KEFS Tower
Test) and a brief interview about their use of diabetes-related technologies.
Adolescents whose BG levels were out of the recommended range performed
more poorly on the SDMT, and those who endorsed more subjective symptomatology
also took longer to make their first move on the Tower Test. Adolescents were fairly
accurate in their BG estimations, most making estimates that were inaccurate but without
clinically serious implications. No relationships were found between continuous glucose
monitor use and BG estimation accuracy. However, participants who reported checking
their BG more frequently per day with a meter made more accurate BG estimations.
Overall, present findings suggest that both immediate BG levels and immediate
symptomatology relate to adolescents’ cognitive function. These results underscore the
importance of considering symptomatology, symptom awareness, and estimation
accuracy in school settings in order to optimize adolescents’ functioning in these settings.

i

ACKNOWLEDGMENTS
Natalie E. Benjamin, B.A.
I would like to thank all who supported this research project. I would first like to
thank the participating adolescents and all the staff members at the diabetes camp where
the data was collected. I would like to extend my appreciation to my committee members,
Dr. Nicholas Heck and Dr. James Hoelzle, for their contributions to this project. I would
especially like to express my gratitude to my advisor and committee chair, Dr. Astrida
Kaugars, for her steadfast support and mentorship throughout this project. Additionally, I
would like to thank the members of the Child and Family Health Lab for their advice and
encouragement.
I would like to thank my parents, Chris and Melissa, and my sister, Emma, for
their unyielding support and enthusiasm for my education and this project. I would like to
thank my partner, Linda, for being an endless source of love and encouragement. Finally,
I would like to thank all my family and friends for their wholehearted support of my
academic endeavors.

ii
TABLE OF CONTENTS
ACKNOWLEDGMENTS ................................................................................................... i	
  
LIST OF TABLES ............................................................................................................. iv	
  
LIST OF FIGURES ............................................................................................................ v
CHAPTER
I.   INTRODUCTION ............................................................................................... 1	
  
T1DM Management .................................................................................... 1	
  
Complications of T1DM ............................................................................. 4	
  
Blood glucose monitoring ........................................................................... 5	
  
Insulin administration ................................................................................. 6	
  
Symptom monitoring .................................................................................. 8	
  
Challenges for adolescents with T1DM .................................................... 11	
  
Cognitive functioning in adolescents with T1DM .................................... 12	
  
Present study ............................................................................................. 13	
  
Hypotheses ................................................................................................ 14	
  
II.   RESEARCH DESIGN AND METHOD ........................................................... 15	
  
Participants................................................................................................ 15	
  
Procedure .................................................................................................. 15	
  
Measures ................................................................................................... 16	
  
Demographic characteristics……………………………….. 16	
  
Symptom survey…………………………………………… 17	
  
Blood glucose estimate…………………………………….. 17	
  
Blood glucose check……………………………………….. 18	
  

iii
D-KEFS Tower…………………………………………….. 18	
  
Symbol Digit Modalities Test……………………………… 19	
  
Technology Interview……………………………………… 19	
  
III.   RESULTS .......................................................................................................... 20	
  
Data Analytic Plan .................................................................................... 20	
  
Participant Characteristics ........................................................................ 23	
  
Hypothesis 1: BG range and total symptomatology scores at the time of
testing will be significantly related to scores on each of the cognitive
measures. Subjective symptomatology will account for more variance in
each cognitive measure than will BG range. ............................................ 24
Hypothesis 2: CGM use frequency will be related to BG estimation
accuracy. ................................................................................................... 25
Additional Exploratory Analyses .............................................................. 27
IV.   DISCUSSION .................................................................................................... 28	
  
Cognitive performance, blood glucose levels, and symptomatology ....... 29	
  
Technology use ......................................................................................... 32	
  
BG Estimation Accuracy .......................................................................... 34	
  
Research Implications ............................................................................... 35	
  
Clinical Implications ................................................................................. 36	
  
Limitations and Future Directions ............................................................ 38	
  
Conclusion ................................................................................................ 40	
  
REFERENCES…………………………………………………………………………..41	
  

iv
LIST OF TABLES
Table 1. Error Grid Analysis Zones……………………………………...………………49
Table 2. Demographic Characteristics………………………...…………………………50
Table 3. Descriptive Statistics of Outcome Variables…………………………………...51
Table 4. Independent Samples T-Test Based on Range of Pre-test Blood Glucose
Levels………………………………………………………………………………….…52
Table 5. Bivariate Correlations Between Cognitive Assessment Scores and Total
Symptomatology…………………………………………………………………………53
Table 6. Central Themes of Helpful CGM Functions…………………………………....54

v
LIST OF FIGURES
Figure 1. Study Procedures…………………………………………………………...….55
Figure 2. Parkes’ Error Grid Analysis…………………………………………….……..56

1
Objective and Subjective Influences on Cognitive Performance
in Adolescents with Type 1 Diabetes
Type 1 diabetes mellitus (T1DM) is one of the most common chronic illnesses in
children and adolescents worldwide, and the negative health risks across the lifespan can
be disabling and even life-threatening (Dabelea et al., 2014). In individuals with this
condition, pancreatic cell destruction (most often due to an autoimmune attack) leads to
insulin deficiency, resulting in an inability to convert food and glucose into energy
(Daneman, 2006). T1DM is most often diagnosed in children and young adults, and
recent data suggest that the incidence of T1DM in adolescents is increasing (Dabelea et
al., 2014). T1DM poses many inherent challenges to adolescents and their caregivers,
including constant disease monitoring and often an invasive treatment regime. Poor
disease management can have deleterious short- and long-term consequences for physical
health and cognitive functioning. Among adolescents, it is important to gain further
understanding about how symptom awareness and blood glucose level impact cognitive
performance and how the use of diabetes monitoring technology affects disease
management.
T1DM Management
Disease management involves an intensive treatment regime that requires families
to shift and fit their lifestyle to the illness. An individual with T1DM must monitor blood
glucose levels and administer insulin appropriately to compensate for the fact that the
pancreas doesn’t produce insulin. Blood glucose levels measure short-term or immediate
glycemic control. Patients monitor their blood glucose levels with finger pricks multiple
times throughout the day, and they administer insulin to adjust blood glucose levels and
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compensate for food consumed. Insulin can be administered by injection or by insulin
pump. Medical professionals encourage individuals with T1DM to aim for blood glucose
levels as close to “normal” (i.e., levels of those without T1DM, also referred to as “inrange” blood glucose levels) as safely possible. Patients’ ability to accomplish this is
referred to as their “metabolic control.” This, however, can be a difficult goal to achieve.
Standards for target glucose levels have been systematically lowered over the past
decade, meaning that medical professionals are asking patients to maintain tighter control
over their disease, although they acknowledge that near-normalization of blood glucose
levels is virtually impossible. Recommendations for glycemic control are often based on
data obtained from studies of adults with T1DM. Target blood glucose levels for children
and adolescents typically range from 90 to 150 mg/dl (American Diabetes Association,
2016a). Special attention must therefore be paid to the risks for hypoglycemia (i.e., low
blood sugar) and hyperglycemia (i.e., high blood sugar) in children and adolescents with
T1DM. Children and adolescents may be less able to recognize symptoms indicative of
hypoglycemia and hyperglycemic, and therefore they may be at greater risk for extreme
blood glucose levels, which can lead to seizures or comas (Silverstein et al., 2005). There
are numerous physiological symptoms that may indicate the presence of hypoglycemia
and hyperglycemia (e.g., thirst, headache, shakiness, etc.), and attention to these
symptoms is an important aspect of diabetes management.
Long-term glycemic control is measured by hemoglobin A1C (HbA1C), which is
an objective measure that reflects one’s average blood glucose level over the past two to
three months (Gonder-Frederick & Cox, 1991). Target levels for glycemic control for
T1DM patients, as recommended by the American Diabetes Association, vary based on
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age and are presented for patients under 6 years of age, 6-12 years of age, and 13 years of
age to adulthood (Silverstein et al., 2005). Therefore, adolescents are expected to meet
similar requirements to adults as they age. For children under 6, an HbA1C value between
7.5% and 8.5% is recommended because of the high risk for hypoglycemia in this age
group. For children between 6 and 12 years old, a value under 8.0% is recommended due
to the lower risk of hypoglycemia and the relatively low risk of complications before
puberty. For adolescents and young adults, a value under 7.5% is recommended due to
higher risk of complications and consideration of developmental and psychological issues
that may co-occur with inconsistent metabolic control.
Individuals with T1DM must also be aware of their diet and nutrition, although
there is little research on specific nutrient requirements for children and adolescents with
diabetes (ADA, 2016a; Donaghue et al., 1997; Weissberg-Benchell et al., 1995). This
may be due to the fact that there is no “one-size-fits-all” eating pattern for individuals
with T1DM that improves glycemic control (ADA, 2016b). Nutrition recommendations
therefore focus on achieving target blood glucose levels and glycemic control without
excessive hypoglycemia (Trumbo, Schlicker, Yates, & Poos, 2002). Regular consultation
with a dietitian is recommended for children and adolescents with T1DM, and meal plans
must be individualized to optimize glycemic control, while also accommodating food
preferences, cultural influences, physical activity patterns, and family eating schedules
and patterns (Silverstein et al., 2005).
Regular exercise provides many benefits for individuals with T1DM, including
but not limited to improved physical fitness, help with weight control (when necessary),
and a greater sense of well being (Wasserman & Zinman, 1994). Excessive exercise is
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related to 10-20% of hypoglycemic episodes and is usually associated with greater than
typical duration, intensity, or frequency of exercise (Silverstein et al., 2005). Exercise is
therefore an important aspect of maintaining good physical health for children and
adolescents with T1DM, just as it is for their healthy peers. However, exercise in
individuals with T1DM often requires close and careful attention in order to avoid
hypoglycemia. Thus, T1DM requires constant monitoring of objective diabetes-related
measures, insulin dosages, and subjective physiological symptoms in order to maintain
optimal physical health.
Complications of T1DM
Lack of metabolic control, caused by inconsistent, frequently high or low blood
glucose levels, can have severe short-term and long-term consequences for patients with
T1DM. In the short term, low blood sugar levels can cause immediate symptoms
including shakiness, sweating, irritability, confusion, rapid heartbeat, dizziness, hunger,
and weakness (ADA, 2016b). High blood sugar levels can immediately cause increased
thirst, frequent urination, headaches, nausea, and diabetic ketoacidosis (DKA), which is a
life-threatening condition in which the body begins to break down fat and muscle for
energy due to a lack of available insulin (Wolfsdorf, Glaser, & Sperling, 2006). Longterm complications typically arise from chronically high blood sugar levels. Overall,
T1DM reduces the normal lifespan by 11 to 13 years and significantly increases the risk
of heart disease and stroke (Livingstone et al., 2015). Kidney damage is one of the most
common long-term complications and can lead to complete kidney failure over time in
approximately 30% of patients with T1DM (National Kidney Foundation, 2015).
Neuropathy in the feet and other extremities is also common; T1DM is responsible for
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more than half of the lower limb amputations in the US every year and is the leading
cause of blindness in adults (ADA, 2016c). Psychologically, T1DM increases one’s risk
for depression and eating disorders (Melendez-Ramirez, Richards, & Cefalu, 2010).
Blood glucose monitoring
Given the potential negative consequences of out-of-range blood glucose levels, it
is crucial that individuals with T1DM, and especially developing children and
adolescents, maintain good metabolic control. Adherence to a strict treatment regimen
involves frequent blood glucose monitoring (i.e., at least four times per day). Selfmonitoring of blood glucose (SMBG) allows individuals with T1DM to measure blood
glucose levels objectively. Studies have shown a strong correlation between the
frequency of blood glucose monitoring and metabolic control (Anderson, Ho, Brackett,
Finkelstein, & Laffel, 1997; Kichler, Kaugars, Maglio, & Alemzadeh, 2012). Frequent
SMBG can help identify patterns of hypoglycemia and hyperglycemia that can inform
insulin dosages. Frequency of SMBG can decrease during adolescence, but studies show
that adolescents with T1DM more accurately and reliably report their SMBG when they
know that their meters are being checked by adults (Sjoeholm, Gray, Rayns, Tomlinson,
& Wheeler, 2016). Results from frequent SMBG and correct interpretation of the results
make effective disease management possible.
In the past few decades, technology development for T1DM management has
accelerated. Use of continuous glucose monitors (CGMs), introduced in 2005, involves
placing a two- to three-millimeter wide sensor under the skin to enable monitoring of
interstitial glucose levels constantly throughout the day. Glucose values are typically
displayed in graph format on a receiver, an insulin pump, or a smartphone (Castle &
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Jacobs, 2016). Ongoing opportunities to monitor blood glucose levels provide infinitely
more data than one receives from finger prick checks four to six times per day. Research
has shown that the use of CGMs in adolescents with T1DM significantly improves their
metabolic control by providing accurate data, promoting patient communication with
medical providers, and enhancing motivation to self-monitor blood glucose levels
(Bergenstal et al., 2010; Schaepelynck-Belicar, Vague, Simonin, & Lassmann-Vague,
2003). However, it is possible that adolescents with access to a deluge of blood glucose
values from these technologies may be less aware of their subjective physiological
symptoms because of their reliance on information from these technologies. Adult CGM
users have been found to rely heavily on CGM data to make adjustments in their insulin
dosages (Pettus & Edelman, 2016). Those who rely on their CGMs to tell them when
their BG levels are out of range might have less of a need to attend to their subjective
symptoms as indicators of BG levels, resulting in symptom unawareness, which could in
turn lead to metabolic control. Conversely, it might be the case that more frequent CGM
use results in increased awareness of how one’s symptoms correspond to out-of-range
BG levels.
Insulin administration
Advances have also been made in insulin delivery over the past few decades.
Insulin administration was originally done exclusively via injection into fatty tissue. The
insulin pump, a method of delivering continuous subcutaneous insulin, was invented and
became popular in the 1970s. The ability to use rapid-acting insulin constantly and to
dose insulin as needed prior to meals or for adjustments was shown to provide better
metabolic control than previous methods involving multiple daily injections and different
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types of insulin (Tamborlane, Sherwin, Genel, & Felig, 1979). In the 1990s, there was a
ten-fold increase in the number of T1DM patients under the age of 20 starting on insulin
pumps (Tamborlane, Bonfig, & Boland, 2001), and both adult and child patients on
insulin pumps have been found to have significantly improved metabolic control (Boland,
Grey, Oesterle, Fredrickson, & Tamborlane, 1999; Tumminia et al., 2015a; Tumminia et
al., 2015b; Weissberg-Benchell, Antisdel-Lomaglio, & Seshadri, 2003; Ziegler et al.,
2015).
Technology use varies considerably from patient to patient; rates of technology
uptake are associated with personal and psychological characteristics, perceptions of and
access to the technology, lifestyle, and existing diabetes management strategies (Kubiak,
Mann, Barnard, & Heinemann, 2016; Naranjo, Tanenbaum, Iturralde, & Hood, 2016).
Additionally, individuals with T1DM do not always consistently use their pumps or
CGMs once they have obtained (de Bock et al., 2016). Adolescents have been found to be
particularly receptive to a variety of diabetes monitoring technologies, and the area of
mobile health has been explored as a possible pathway for intervention with this
population and their caregivers (Wagner et al., 2016). One study found that 96% of
caregivers of children with diabetes had access to the internet, and 64% used the internet
for diabetes resources, predominantly social media (Balkhi, Olsen, Lazaroe, Silverstein,
& Geffken, 2015). Many smartphone apps exist to aid diabetes self-management; most
apps focus on BGM recording, food and insulin tracking, and insulin dosage calculating
(Demidowich, Lu, Tamler, & Bloomgarden, 2012). Research shows that ease of use and
real-time access to diabetes data make these technologies appealing to both parents and
children (Prakasam, Rees, Lyden, & Parkin, 2016).
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In sum, there has been a significant increase over the last twenty years in the
technology available for T1DM patients and in the use of that technology by adolescents.
Most of these technologies have been found to significantly improve glycemic control
and diabetes care. However, it is important to explore the relationship between
technology use and adolescents’ awareness of their physiological symptoms.
Symptom monitoring
Individuals with T1DM vary in their ability to detect symptoms of high or low
blood glucose levels. Recognition of subjective physiological symptoms is crucial to the
behavioral model of disease management, as physiological symptoms provide immediate
and direct information about health status (Nerenz & Leventhal, 1983). Symptom
perception in diabetes can be defined as “conscious awareness of or ability to detect
physical sensations associated with hypo- and hyperglycemia (e.g., pounding heart,
shakiness) that result from blood glucose fluctuations” (Lane, 2006, p. 233). Individuals’
awareness of their subjective physiological symptoms may provide information about
hyperglycemia and hypoglycemia. Typical symptoms may include headache, nausea,
thirst, hunger, sweating, shakiness, and many others, depending on the individual and the
associated blood glucose level Some individuals have a set of symptom beliefs (i.e.,
thoughts or beliefs that certain physiological symptoms correspond to certain blood
glucose levels) that help them guide self-treatment decisions, and some do not. The use of
subjective physiological symptoms to monitor one’s blood glucose levels is dependent
upon the assumption that one’s subjective symptomatology is an accurate and reliable
indicator of one’s objective blood glucose, which may not be the case for all individuals.
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It is also important to note that not all individuals will have the same symptoms
relating to the same blood glucose levels. Studies show that both hypoglycemia and
hyperglycemia can be symptomatic, but that there are no specific symptoms that covary
with either hypoglycemia or hyperglycemia across patients (Freund, Bennett-Johnson,
Rosenbloom, Alexander, & Hansen, 1986; Gonder-Frederick & Cox, 1991). However,
hypoglycemia is generally associated with more symptoms that are also more severe in
nature and may be slightly more consistent across individuals. Additionally, blood
glucose level thresholds at which individuals begin to feel symptomatic are not the same
for all patients (Gonder-Frederick & Cox, 1991). Thus, all diabetes-related
symptomatology is quite idiosyncratic, and general statements cannot be made about
which symptoms apply to which blood glucose levels (Lane, 2006).
Because of aforementioned serious, long-lasting consequences of poor metabolic
control, it is important that individuals with T1DM recognize their symptoms and use this
information to guide their decisions about whether and when to check their blood sugar
and follow up with appropriate adjustments.
Studies in this area must therefore be careful to focus on within-subjects patterns
and differences. In light of this, we can ask two main questions related to an individual’s
subjective diabetes-related symptoms: To what extent do individuals’ own subjective
physiological symptoms reliably covary with their blood glucose fluctuations, and to
what extent do T1DM patients accurately recognize and label their symptoms?
There is no linear relationship between physiological events and one’s subjective
perceptions of those events. All of these relationships will vary both across individuals
and within individuals; therefore, one cannot assume that all individuals experience the
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same physiological events in reaction to the same blood glucose levels. Related research
shows that adults make clinically serious errors in their blood glucose estimations up to
20% of the time, and that adolescents are significantly worse at estimations than are
adults and make similarly serious errors approximately one-third of the time (Cox et al.,
1985; Gonder-Frederick, Snyder, & Clarke, 1991; Lane, 2006). These errors most
commonly consist of failure to detect extreme levels of blood glucose (more often
hyperglycemia than hypoglycemia), which can lead to under- or over-corrective
treatments (Gonder-Frederick et al., 2004; Kovatchev, Cox, Gonder-Frederick, Schlundt,
& Clarke, 1998; Lane & Heffer, 2005 as cited in Lane, 2006). It is therefore evident that
T1DM patients’ awareness of their subjective physiological symptoms can affect their
disease management.
Researchers in the early 1990’s developed a program called Blood Glucose
Awareness Training (BGAT; Gonder-Frederick, Cox, Clarke, & Julian, 2000). This
program aims to increase the ability of individuals with T1DM to accurately perceive and
interpret their own blood glucose levels. This includes recognizing hyperglycemia and
hypoglycemia and identifying patterns and errors in one’s perceptions. The training aims
to improve patients’ ability to recognize which symptoms correspond to which blood
glucose levels. It is then expected that patients’ metabolic control will also improve via
increased recognition of out-of-range blood sugars and more timely responses to those
blood sugars. Studies investigating effectiveness of the intervention with pre- and posttest designs have found improved accuracy in detecting blood glucose fluctuations and
better detection of both hyperglycemia and hypoglycemia (Cox et al., 1989; Cox et al.,
1995). Thus, individuals with T1DM can use the information gained from their
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experience of specific symptoms to guide decisions of if, when, and how to regulate their
blood glucose.
Challenges for adolescents with T1DM
In addition to the inherent challenges of managing T1DM, adolescents with this
disease must also grapple with the developmental changes occurring at this time.
Adolescence is a period of rapid biological development and increasing emotional,
cognitive, and physical maturity that is often characterized by individuals’ search for
their autonomy and independence from their parents or caregivers (Herzer & Hood,
2010). This is especially salient in the context of chronic illness management. Moreover,
adolescence can trigger changes in insulin sensitivity related to physical growth and
sexual maturation, in addition to a neurological vulnerability to hypoglycemia and
hyperglycemia (Barnea-Goraly et al., 2014). These particular biological changes may
contribute to challenges in managing T1DM.
In childhood, diabetes management tasks are primarily the responsibility of the
parents or caregivers. During adolescence, this responsibility begins to transfer to the
adolescent in preparation for adulthood. This transition period can be one of the most
difficult times for adolescents with T1DM (Garvey, Markowitz, & Laffel, 2012). Because
adolescents are physically able to complete adherence tasks, parents are sometimes
tempted to quickly hand all responsibility to their teenagers. However, while adolescents
may be physically prepared for the increased responsibility, they often need help with the
decision making and planning required to execute T1DM management tasks successfully
(Herzer & Hood, 2010). This may leave adolescents with T1DM feeling unsupported and
vulnerable, which can lead to an avoidance of self-care and follow-up care from medical
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providers. Disease management and treatment adherence may therefore often not be a
priority for adolescents with T1DM (who may choose to pursue more typical ageappropriate activities), and metabolic control often decreases as a result (Garvey et al.,
2012). Because of these developmental changes, adolescents’ increased responsibility for
disease management tasks necessitates an acquisition of new skills and an increased
awareness of their bodies’ signs and signals indicating low and high blood sugars.
Cognitive functioning in adolescents with T1DM
Metabolic control may also impact cognitive functioning. Glucose is virtually the
sole source of fuel for the human brain, which lacks fuel stores and hence requires a
continuous supply of glucose. In addition to consuming glucose for general functioning,
glucose use can also be tracked during shorter periods of cognitive effort. Studies have
shown that individuals without diabetes whose blood glucose levels decreased during a
cognitive task performed better on the task than those whose BG levels did not change
during the task (Galanina et al., 2008); it is hypothesized that their brains were efficiently
using glucose to complete the task. Furthermore, adult subjects without diabetes who
consumed a glucose drink immediately prior to a cognitive task also performed better on
the task than those who did not consume the drink (Scholey, Harper, & Kennedy, 2001).
Importantly, glucose consumption would not be an energy asset in individuals with
diabetes, who might develop hyperglycemia in reaction to the glucose intake. Thus, it is
important to better understand the impact of glucose levels in adolescents with T1DM
prior to a cognitive task.
In children and adolescents with diabetes, cognitive performance is commonly
studied in relation to children and adolescents without diabetes. Results consistently show
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that when compared to children without diabetes, children with diabetes perform more
poorly on various neuropsychological and cognitive assessments, especially in the areas
of psychomotor speed, mental flexibility, and attention (Brands, Kessels, de Haan,
Kappelle, & Biessels, 2004; Moheet, Mangia, & Seaquist, 2015). Differences between
these two groups are more pronounced in children with earlier onset diabetes (Gaudieri,
Chen, Greer, & Holmes, 2008). However, unlike research on individuals without
diabetes, there is no existing literature addressing the relationship between immediate
blood glucose levels and cognitive performance in individuals with diabetes. Symptoms
such as headaches, nausea, or shakiness may impact an individual’s ability to attend to
tasks or information and make appropriate decisions when completing a cognitivelydemanding task. Given the potential effects of blood glucose level and symptomatology
on daily cognitive functioning in children and adolescents with diabetes, an
understanding of the relationship between these variables is a critical aspect of disease
management in this population.
Present study
In light of the information presented thus far, this study examined the similarities
and differences between objective and subjective diabetes-related variables and their
respective relationships to cognitive performance. In order to accomplish this, objective
and subjective measures of blood glucose and physiological symptoms were assessed.
Many studies examining psychological and physiological factors in individuals
with T1DM measure HbA1C, which indicates metabolic control over a long-term period of
time. Typically, HbA1C levels over time have been examined in relation to cognitive
functioning (e.g., Brands, Biessels, de Haan, Kappelle, & Kessels, 2005). Conversely, the
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present assessed blood glucose immediately before the completion of two cognitive tasks
in order to better understand how the participants’ objective blood glucose level at the
time of the task may be related to task performance.
This study examined potential predictors of cognitive performance and whether
one’s objective blood glucose levels or subjective physiological symptoms are better able
to predict performance on tasks of processing speed and executive functioning. The study
also investigated adolescents’ ability to predict their own blood glucose levels and
whether adolescents’ use of diabetes-related technology was associated with their
prediction accuracy. This is an area that has yet to be explored.
In order to assess subjective symptomatology and technology use, assessments
were developed for this purpose (i.e., a symptom checklist and a semi-structured
interview on technology use). This study was the first to explore all of these variables in
adolescents, and findings will inform medical, mental health, and educational
professionals about the impact of various diabetes-related outcomes on adolescents’
functioning in school and other settings.
Hypotheses
The hypotheses tested in the current study were as follows:
1.   Blood glucose range (i.e., whether participants’ BG levels were in or out of the
recommended 90 to 150 range) and subjective symptomatology (i.e., the
combined severity of each experienced symptom) at the time of testing will be
significantly related to scores on each of the cognitive measures.
a.   Blood glucose range will be negatively related to scores on both the DKEFS Towers and the Symbol Digit Modalities Test, such that
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participants whose blood glucose levels are out of range will perform
more poorly on these cognitive tasks.
b.   Subjective symptomatology will be negatively related to scores on both
the D-KEFS Towers and the SDMT, such that participants experiencing
increased levels of physiological symptoms will perform more poorly on
these cognitive tasks.
c.   When considering the influence of both blood glucose deviation and
subjective symptomatology on cognitive performance, subjective
symptomatology will account for significantly more variance in each
assessment than will blood glucose deviation.
2.   Significant differences in blood glucose prediction accuracy will be found based
on the frequency of individuals’ technology (i.e., pump and CGM) use.
Research Design and Method
Participants
Eligible participants included adolescents aged 13 to 17 years with a current
diagnosis of type 1 diabetes. Potential participants with a diagnosis of type 2 diabetes
were excluded from the study.
Procedure
Participants were recruited from the group of 120 adolescents registered for a teen
diabetes camp in the summer of 2016. The camp director sent information about the
current study and the investigators via email to parents of adolescents registered for the
July 2016 camp. Those families interested in participating completed online parent
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permission forms. In-person recruitment also took place immediately before the start of
camp; experimenters were present at various drop-off locations and approached families
about the study. Those families who expressed interest but had not yet completed online
consent materials were given the opportunity to do so in-person.
Adolescents with parental permission for their participation were approached
during the camp session and asked if they were still interested in participating in the
study. Those who were interested first completed the assent process with one of two
experimenters: the principal investigator or a female undergraduate research assistant.
Participants did not receive any compensation for their participation.
After adolescents provided their individual assent to participate in the study, they
completed a variety of tasks relating to objective blood glucose assessment, subjective
symptom perception, cognitive capabilities, and their use of diabetes monitoring
technologies. Testing took place in a private room in the camp’s medical building. The
study session lasted approximately 30 to 40 minutes. The order of most of the tasks was
standardized (see Figure 1) with the exception of the administration of the two cognitive
assessments, which were administered in a randomized counterbalanced order.
Measures
Demographic characteristics.
Adolescents were asked to report on their date of birth, diabetes diagnostic status
(i.e., confirmation of T1DM diagnosis), age and date of diagnosis, gender, grade in
school, race, ethnicity, and zip code. Median income per zip code was taken from data
spanning 2006 to 2010 from the University of Michigan Population Studies Center.
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Demographic variables were collected to describe the study sample and were used to
assess for potential differences based on demographic characteristics. Time of testing and
camp activities for the preceding two hours were recorded.
Symptom survey.
Participants completed a brief survey in which they indicated which, if any, of 22
subjective physiological symptoms they were currently experiencing (see Appendix A).
This symptom survey included both common and uncommon symptoms of hypoglycemia
and hyperglycemia. The symptom survey was developed based on previous literature that
explored blood glucose symptomatology in individuals with T1DM (Gonder-Frederick &
Cox, 1991). For each symptom, participants used a Likert scale to rate the intensity of the
symptom ranging from 1 (a little bit) to 5 (a lot); thus; higher scores indicate more severe
symptomatology. Scores for each symptom inventory (pre- and post-test) were generated
by taking the mean of all symptom intensities for each of the two surveys completed. The
two resulting scores were found to be highly correlated (r = .81, p < .001); thus, the preand post-test symptom scores were averaged, resulting in one score reflecting
participants’ subjective symptomatology at the time of testing.
The symptom survey also asked participants to provide an overall estimate of
their current blood glucose level: low, in range, or high. This allowed for examination of
inter-individual differences in the types of symptoms that are associated with blood
glucose estimates.
Blood glucose estimate.
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Participants were asked to estimate their current precise blood glucose level,
which was recorded.
Blood glucose check.
Participants were asked to check their blood glucose level using their own meter
and supplies. This value was recorded.
D-KEFS Tower.
The Delis-Kaplan Executive Function System (D-KEFS; Delis, Kaplan, &
Kramer, 2001) is a set of nine standardized tests that measure a wide spectrum of verbal
and nonverbal executive functions. The Tower subtest evaluates spatial planning, rule
learning, inhibition of impulses and perseverative responding, and the ability to establish
and maintain an instructional set. This subtest places demands on multiple aspects of
executive functioning and draws on several aspects of goal-directed behavior (e.g.,
planning ahead while keeping rules in mind). It was selected for this study because of its
demands on cognitive function and sustained attention. The D-KEFS was standardized on
a nationally representative, stratified sample of 1,750 non-clinical children, adolescents,
and adults ages 8 to 89 years (Homack, Lee, & Riccio, 2005). Moderate levels of testretest reliability have been found on this task in 8- to 19-year-olds (Fisher, 2009).
Administration takes approximately 10 minutes. Total Achievement, Mean First Move
Time, and Time-Per-Move scaled scores were used for analyses. These scores range from
1 to 19, with a mean of 10 and a standard deviation of 3. The Total Achievement score is
calculated based on how many towers are correctly completed in the allotted time and on
how many moves were required to complete them (Yochim, Baldo, Kane, & Delis,
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2009). Mean First-Move Time reflects the speed with which participants completed their
first move on each item. Time-Per-Move ratio analyzes the average time a participant
takes to make each of his or her moves (not just first moves). Higher scores represent
more success on this subtest.
Symbol Digit Modalities Test.
The Symbol Digit Modalities Test (SDMT; Smith, 2000) is a cognitive
assessment that measures attention, concentration, and speed of information processing.
The test involves a substitution task wherein participants use a reference key to pair
numbers with given geometric figures during a period of 90 seconds. There are oral and
written forms of the test; for this study, the oral version was used to minimize effects due
to differences in motor skills between participants. Test-retest reliability has been found
to be good (Bate, Mathias, & Crawford, 2001). It is validated for use in individuals 8
years of age and older (Smith, 2000). This test was selected for the present study because
it assesses cognitive function and processing speed. Administration typically takes 5
minutes or less. Standard scores range from 50 to 150, with a mean of 100 and a standard
deviation of 15.
Technology Interview.
Participants took part in a brief (5- to 10-minute) semi-structured interview
assessing their use of diabetes monitoring technology (see Appendix B). Questions
inquired about which available technologies they use (e.g., blood glucose meters, insulin
pumps, continuous glucose monitors), how often they use each technology, and how
often they or their parents download and/or review data from said technologies. This

20
interview was developed for the present study based on literature exploring the
assessment and monitoring of metabolic control in children and adolescents with T1DM
(Rewers et al., 2009; Yeh et al., 2012). This survey yielded quantitative and qualitative
descriptive information about participants’ technology use. Quantitative scores derived
from this interview included the following: 1) a variable indicating whether participants
use insulin pumps and/or continuous glucose monitors (“technology use”); 2) a variable
reflecting the frequency with which participants who have CGMs look at the data daily
(“CGM look frequency”); 3) a variable reflecting the number of day in the past month
individuals who have CGMs used them (“CGM use”); and 4) a variable reflecting the
frequency with which participants checked their blood sugar daily (“BG check
frequency”).
Results
Data Analytic Plan
Statistical analyses were conducted using SPSS 24.0 (IBM Corp., 2016) and R
statistical computing software (R Core Team, 2014). To address the first set of
hypotheses examining symptom reports, numerical scores were generated from the preand post-test symptom surveys by averaging the intensity ratings for each of the
symptoms endorsed. These two scores were highly correlated, r = .81, p < .001. Because
no significant difference was found between them, a mean of the two scores was
calculated and used in analyses. This variable, the total symptomatology score, was found
to be significantly positively skewed (skew = 5.57). Thus, a square root transformation
was conducted; the resulting variable had a skew value of 0.84.
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BG values for pre- and post-test were used to generate corresponding
dichotomous values reflecting whether or not each value was in the recommended range
for adolescents (i.e., 90-150 mg/dl; ADA, 2016). These values will be referred to as BG
range values (i.e., in range score = 1, out of range score = 2).
Standard scores for the D-KEFS Tower Total Achievement, Mean First Move
Time, and Time-Per-Move were calculated using standard guidelines (Delis, Kaplan, &
Kramer, 2001). These scores range from 1 to 19, with an average of 10 and a standard
deviation of 3. Total standard scores for the SDMT were also calculated per standardized
guidelines (Smith, 2002); these range from 50 to 150 with an average of 100 and a
standard deviation of 15.
Independent samples t-tests were conducted to explore group differences on DKEFS Tower and SDMT scores based on whether participants’ BG levels were in range
or out of range. Bivariate correlations were conducted to explore relationships among
total symptomatology scores, D-KEFS Tower scores, and SDMT total scores. Multiple
regression analyses were conducted to evaluate the amount of variance in cognitive
scores accounted for by an individual’s subjective physiological symptomatology and
blood glucose range.
To address the second hypothesis, information from the technology interview was
used to create a categorical technology use variable, reflecting whether participants used
an insulin pump and/or a CGM (0 = neither, 1 = one or the other, 2 = both). Only one
participant reported using a CGM but not a pump; hence, all participants who used one
but not both technologies were combined into one group. Technology interviews were
also used to create a CGM monthly use variable (i.e., reflecting the number of days in the
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past month adolescents reported using their CGM) and a CGM look frequency variable
(reflecting the number of times per day adolescent reported looking at his or her CGM
data).
An error grid analysis (EGA) package of R (Schmolze, 2015) was used to
calculate the accuracy of participants’ blood glucose estimations. EGA was developed for
this specific purpose and is commonly used in research examining BGAT programs
(Cox, Gonder-Frederick, Kovatchev, Julian, & Clarke, 1997; Cox et al., 2001). EGA
involves plotting estimated and observed blood glucose levels on a grid and observing
clinical zones into which the intersection points fall. EGA differentiates between
clinically benign and clinically significant errors (Lane, 2006). The original EGA detailed
the clinical significance of the difference between two BG values (Clarke, Cox, GonderFrederick, Carter, & Pohl, 1987). Zones of accuracy (A through E) were developed based
on numerical discrepancy between values. Parkes, Slatin, Pardo, and Ginsberg (2000)
critiqued this original error grid on the basis that it overlooked certain risk categories and
was based on outdated standards of clinical care. They developed a new error grid
wherein zones of accuracy were based instead upon clinical judgment of medical
professionals, who assigned errors to five risk categories. The resulting zones describe
the risk of erroneous BG measurements (see Table 1 for zone criteria). For the purposes
of this study, results from Parkes’ EGA (2000) were used given its clinically-relevant
approach to zone assignment.
The technology use variable was entered into a multiple regression analysis
predicting EGA zones to determine the amount of variance in estimation accuracy
accounted for by technology use.
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Technology interviews were reviewed to identify primary themes that emerged in
adolescents’ discussions of the most helpful aspects of their CGMs. The primary
investigator reviewed participants’ qualitative responses and identified central themes;
two research assistants then identified which themes were reflected in each participant’s
response. The research assistants agreed on 80.6% of the ratings. Agreement was
calculated by dividing the number of agreed upon codes assigned by the total number of
codes assigned. Ratings with disagreements were discussed with the primary investigator,
and final ratings were determined.
A priori power analyses were conducted using G*Power 3.1.92 (Faul, Erdfelder,
Buchner, & Lang, 2009) with a moderate effect size (f2 = 0.15 for linear multiple
regression). These analyses indicated that a total of 107 participants would be necessary
to ensure that statistically significant effects are found for the multiple regression if they
truly exist at the level of a = .05. Unfortunately, there is no previous literature that could
guide effect estimates. Given that this is a preliminary study and the limitations of
recruitment from this population, effect sizes will be included in these analyses when
relevant.
Participant Characteristics
Analyses were based on a sample of 55 adolescent participants. Descriptive
statistics for demographic variables can be found in Table 2. All participants identified as
having type 1 diabetes. Participants ranged in age from 13 to 17 years (M = 15.11, SD =
1.06). The majority of participants identified as Caucasian (87.2%). Furthermore, 3.6% of
participants identified as American Indian or Alaska Native, Asian, or Black or African
American, respectively. Sixteen-point-four percent of participants identified as Hispanic
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or Latino/a. Based on self-reports, adolescents’ mean age at diagnosis was 7.74 years (SD
= 3.86).
Descriptive analyses for adolescents’ performance on each of the cognitive
assessments (SDMT and D-KEFS Tower Test) and for total symptomatology endorsed
by participants can be found in Table 3. At pre-test, 34.5% of participants’ BG levels
were in range, and the remaining 65% were out of range. A significant relationship was
found between age at diagnosis and median income, r = .36, p = .01, such that those
diagnosed at an older age were more likely to live in a zip code with a higher median
income. Additionally, a significant relationship was found between age at diagnosis and
D-KEFS Tower Time Per Move scores, r = -.27, p = .05; participants diagnosed at an
older age took longer to perform each move on the D-KEFS Tower test. No other group
differences on any of the variables of interest were found based on demographic variables
listed in Table 2.
Hypothesis 1: BG range and total symptomatology scores at the time of testing will
be significantly related to scores on each of the cognitive measures. Subjective
symptomatology will account for more variance in each cognitive measure than will
BG range.
Analyses were conducted exploring group differences in cognitive performance
based on whether individuals’ blood glucose levels were in or out of range. Significant
group differences were found on the SDMT total scores, such that those participants
whose BG levels were in range performed significantly better on the SDMT than did the
participants whose BG levels were out of range, t(47) = 1.98, p = .05. Participants whose
BG levels were in range at pre-test also reported significantly higher total
symptomatology than those whose BG levels were out of range, t(53) = 2.03, p = .04. The
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effect sizes for these two group differences were in the medium range (0.53 and 0.58,
respectively; see Table 4). No other group differences on cognitive performance were
found based on pre-test BG levels. Test statistics can be found in Table 4.
Additionally, bivariate correlations were conducted to assess the relationship
between total symptomatology and each of the cognitive scores. A significant
relationship was found between total symptomatology and Tower Mean First Move
Time. Adolescents who reported higher levels of symptomatology had a slower mean
first move time across the nine items on the Tower test, r = -.31, p = .01. Total
symptomatology thus accounted for 16% of the variance in Tower Mean First Move
Time scores. No significant relationships were found between the total symptomatology
variable and any other cognitive scores.
Hypothesis 2: CGM use frequency will be related to BG estimation accuracy.
EGA was conducted on both pre- and post-test BG estimates and values.
However, post-test BG estimates were made only 15 to 20 minutes after participants had
checked their BG at pre-test; hence, participants were fairly accurate in their post-test
estimates and little variance in accuracy was found. Estimation accuracy at post-test was
therefore not thought to be an authentic reflection of participants’ estimation abilities, and
thus only estimation accuracy at pre-test will be reported and discussed in analyses.
Parkes’ EGA were conducted on estimated and actual BG values at pre-test.
Participants’ estimations were in the following zones: 38.2% were in Zone A; 60.0%
were in Zone B; and 1.8% were in Zone C (see Table 3 and Figure 2).
Based on the technology interview, 10.9% of participants reported using neither a
CGM nor a pump; 23.6% reported using one or the other; and 65.5% reported using both.
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A chi-square test of independence was conducted to examine the relation between
technology use and EGA zone; the relation between these variables was not significant,
c2(4) = 0.96, p = .92. One-way analyses of variance were conducted to assess for group
differences in total symptomatology scores, SDMT total scores, and the three Tower
scores based on technology use; no significant group differences were found.
The following analyses examined only participants who reported using a CGM (n
= 37). One-way ANOVAs were conducted to examine potential differences in CGM look
frequency and CGM monthly use based on BG estimation accuracy; no significant group
differences were found. Within this sample, CGM look frequency was found to be
significantly related to total symptomatology. Participants who reported looking at their
CGM data more frequently also reported higher total symptomatology, r = .35, p = .04.
CGM look frequency and CGM monthly use variables were entered into a linear
regression predicting total symptomatology; the model was found to be significant, F(2,
33) = 5.46, p = .01, with an R2 value of .25, indicating that the CGM-related variables
accounted for 25% of the variance in total symptomatology. Notably, increased CGM
look frequency but decreased CGM monthly use predicted increased total
symptomatology.
When asked about the most helpful aspects of the CGM technology, five primary
themes emerged (see Table 6). Over half (56.8%) of participants indicated that using the
CGM increases their awareness of their BG level, especially in cases of hyperglycemia or
hypoglycemia. For example, one participant stated, “It alerts me when I’m going high,
because I don’t notice.” Thirty-seven percent of participants reported finding the CGM’s
arrows (indicating whether BG values are rising or falling and at what rate) and the
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graphs of BG values over the course of the day to be helpful. For example, one
participant stated, “It’s good to see the trend arrows, it provides more information.”
Twenty-seven percent of participants indicated that the CGM gives them advance notice
of BG changes so that they can make timely adjustments with food or insulin; for
example, one participant reported, “It lets you know where your blood sugar is going
before you’re super high or super low.” Twenty-four percent of adolescents reported that
the CGM is helpful in providing general information or data about their BG levels,
including one participant who stated, “It’s good for more data. This is a condition about
data and knowing what’s going on and how to respond.” Lastly, 21.6% of participants
note that the CGM is more convenient than other methods of BG management. One
participant reported, “it gives me a break from checking with holes in my fingers; it’s
easier.”
When asked to rank the helpfulness of their CGM on a scale of 1 (not helpful at
all) to 10 (extremely helpful), 75.6% of participants with CGMs indicated an 8 or higher
(M = 8.27, range: 4-10).
Additional Exploratory Analyses
Based on analyses to address the proposed hypotheses, additional questions arose
about the data. Thus, exploratory analyses were conducted to better understand two main
areas of interest.
Rates of endorsement of individual subjective symptoms were explored.
Independent samples t-tests were conducted to examine differences in individual
symptom endorsement based on BG values. Participants whose BG values were out of
range reported significantly higher levels of thirst than those who were in range, t(52) = -
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2.20, p = .03, but significantly lower levels of fatigue, t(27) = 2.39, p = .02, and feeling
weak, t(22) = 2.36, p = .03.
Subsequently, differences in individual symptom endorsement between
participants who reported feeling in range or out of range were examined. Participants
who felt out of range (i.e., high) endorsed significantly higher levels of thirst at pre-test,
t(52) = -3.07, p = .003, and at post-test, t(52) = -2.55, p = .01, and higher levels of dry
mouth at post-test, t(17) = -2.10, p = .05. Additionally, participants who reported feeling
out of range (i.e., high) at pre-test had higher objective BG values than those who
reported feeling in range, t(17) = -3.33, p < .001.
Given the limited existing information on Parkes’ EGA zones in this population,
preliminary analyses examined what variables might be related to zone classification.
Participants whose BG estimations were accurate enough to have no effect on clinical
action (i.e., in Zone A) reported checking their BG (via meter) more frequently than those
whose estimates were less accurate (i.e., Zone B or C), t(28) = 2.19, p = .04.
Discussion
The current study explored relationships among blood glucose levels, subjective
physiological symptomatology, and cognitive performance in adolescents with type 1
diabetes. This study also examined the use of diabetes technology in this population and
the accuracy with which adolescents can predict their current BG levels. This study was
the first to explore the relationship between immediate, in-the-moment BG levels and
cognitive performance in adolescents with T1DM. This study was also unique in its
application of error grid analysis to the BG estimation of these adolescents.
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Consistent with hypotheses, BG levels and subjective symptomatology were each
distinctly related to various aspects of adolescents’ cognitive performance. Contrary to
hypotheses, no aspect of technology use was found to be related to adolescents’ BG
estimation accuracy. Within the group of adolescents who used continuous glucose
monitors, monthly use and look frequency were related to the subjective symptomatology
participants endorsed. General symptom endorsement did vary based on BG levels,
although it seemed more dependent upon how participants reported feeling than on their
objective BG levels. Notably, participants who reported checking their BG with a meter
more frequently per day did make more accurate BG estimations.
Cognitive performance, blood glucose levels, and symptomatology
The hypothesis that objective BG level and total subjective symptomatology
would each be related to scores on all cognitive assessments was not supported. Instead,
BG level (i.e., whether participants’ BG values were in or out of the target range based on
ADA standards for adolescents; ADA, 2016b) and total subjective symptomatology were
found to be significantly related to different cognitive assessment scores.
BG values were significantly related to scores on the SDMT; specifically,
participants whose BG values were within the target range at the time of testing
performed significantly better on the SDMT. The SDMT is a well-validated measure
often used to assess neurocognitive functions including attention, visual scanning, and
processing speed. It is also widely used to assess for neurological impairment and is
accepted as a measure that is sensitive to such impairments (Sheridan et al., 2006). Thus,
it is possible that the SDMT is most affected by subtle differences in BG values because
of its sensitivity to attention and immediate, in-the-moment processing. Existing research
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shows that, in adults with T1DM, hyperglycemia is associated with impairment on
various cognitive-motor tasks (Cox et al., 2005).
Subjective symptomatology, on the other hand, was found to be related to the DKEFS Tower Mean First Move Time score. The D-KEFS Tower Test involves deliberate,
prospective thinking in the planning of one’s future moves. The Mean First Move Time
score assesses the average speed with which participants make their first move in the
Tower Test across all nine items. This subscale score of the Tower test has been related
in existing literature to planning ability and problem solving skills (Jacobs & Anderson,
2002; Yochim et al., 2009). On average, individuals who endorsed more subjective
symptomatology at the time of testing also took longer to make their first move. This
implies that physiological symptomatology may negatively affect adolescents’ ability to
process and plan their approach and strategy. Following this logic, performance on the
SDMT would not be as affected by increased symptomatology because the task does not
require planning; rather, it involves only matching numbers to symbols and therefore
does not necessitate prospective thinking or strategizing. It is this distinction that may
explain the differences in the pattern of significant relationships between cognitive
measures and diabetes indicators.
It is possible that symptomatology was not related to the overall D-KEFS Tower
Time-Per-Move Score because the Time-Per-Move score accounts for speed across all
moves in the task, not just the first move of each item. Thus, if symptomatology affects
planning ability, it appears that this effect is most apparent at the outset of each item
administered. Notably, the D-KEFS Tower Total Achievement Score was also unrelated
to either diabetes indicator, consistent with the speculation that symptomatology has a
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subtle impact on this particular cognitive task, as opposed to a broad, general impact. It
should be mentioned that it is difficult to know whether differences between cognitive
assessments found in the present study are artifacts of the small sample size, or whether
these are true effects that can be applied to larger population. A larger sample size would
elucidate these distinctions further.
Because different cognitive assessment scores (i.e., the SDMT and the Tower
Mean First Move Time) were related to different diabetes variables (i.e., BG values and
subjective symptomatology), it is impossible to say which diabetes variable was “more”
related to general cognitive function, as proposed in Hypothesis 1. Rather, it appears that
these cognitive functions are related in different ways to the various diabetes outcomes.
Since subjective symptomatology was significantly related to certain aspects of cognitive
function in this population, caretakers and teachers should consider monitoring
symptomatology, in addition to objective BG levels, in individuals with T1DM.
Interestingly, adolescents whose BG levels were in range endorsed significantly
more subjective symptomatology than did those whose BG levels were out of range. This
finding confirms previous research stating that physiological symptoms do not reliably
covary with objective BG levels across patients (Gonder-Frederick & Cox, 1991). In this
sample, increased symptomatology as a whole was not associated with out-of-range
blood sugars. That said, certain individual symptoms (e.g., thirst) were endorsed more by
those participants who indicated feeling out of range; thus, it is likely that certain
symptoms might be found to covary reliably with high or low BG values in a larger
sample. Taken together, these results illustrate the inconsistency of the relationship
between BG values and subjective symptomatology and highlight the importance of
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attending equally to symptomatology and objective BG values when targeting optimal
cognitive functioning in these individuals.
Technology use
As a group, this sample reported high usage levels of diabetes technology. Eightyseven percent of participants reported using a pump, and 67.3% used a CGM. In contrast,
recent data from the T1D Exchange clinic registry indicated that 58% of adolescents
between the ages of 13 and 17 used insulin pumps, and only 5% used CGMs (Miller et
al., 2015). This relatively high rate of technology use in the present population might
reflect certain characteristics about individuals who attend diabetes camps. Specifically,
campers and their families may prioritize their disease management and are therefore
motivated to both use the latest technology and attend camp to improve patients’ disease
management and outlook. Research conducted at diabetes camps indicates that camp
attendance improves diabetes knowledge, subjective coping abilities, and general
attitudes toward diabetes in children and adolescents with T1DM (Santiprabhob et al.,
2008; Viklund, Rudberg, & Wikblad, 2007).
Contrary to the second hypothesis, general technology use (i.e., whether
participants reported using a pump, a CGM, both, or neither) appears to be unrelated to
BG estimation accuracy. Thus it does not appear that individuals’ use of technology
influences their awareness of their BG level, or if it does, this awareness does not
translate into increased estimation accuracy. It is also possible that some participants
reported owning or having a certain technology without using it frequently enough to
affect their awareness or accuracy. Research regarding patterns of CGM use in
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adolescents is sparse, but it suggests that usage is quite variable among adolescents who
own CGMs (Naranjo et al., 2016).
In examining reports from participants using CGMs, monthly use (i.e., number of
days in the past month individuals reported using their CGM) and look frequency (i.e.,
the number of times per day individuals reported looking at their CGM data) were found
to predict subjective symptomatology. Specifically, participants who reported using their
CGM fewer days in the past month and those who reported looking at their CGM data
more daily endorsed higher symptomatology. This finding has interesting implications
for different CGM usage patterns. First, it seems that participants who simply attach their
CGM without regularly attending to it are less aware of their symptomatology. It is
possible that these individuals do not monitor their CGMs closely because the CGM
monitors their BG level for them and alarms when BG levels fall outside a given range.
These individuals are likely less aware of symptoms they experience, because they rely
solely on their CGM to tell them when their BG levels are out of range. Conversely,
participants who look at the CGM data more often each day might use the CGM more as
a way to inform them about how certain symptoms correspond to certain BG levels. It
might also be the case that adolescents who experience more symptoms attend to their
CGM more, in order to reconcile their experienced symptoms with their current BG level.
Encouragingly, the vast majority of participants using CGMs found them to be
extremely helpful. Based on adolescents’ responses to an open-ended question about the
most useful features of the CGM, the majority of CGM users indicated that the alerts for
low or high BG values were invaluable. Participants’ answers also suggested that CGMs
are an easy way to get a large amount of data (a BG value is provided every 5 minutes, 24
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hours a day), and that this data is often information they wouldn’t otherwise have. That
many participants identified the trend arrows as a particularly helpful feature is consistent
with research showing that adults with T1DM rely heavily on these arrows when making
insulin dosage decisions (Pettus & Edelman, 2016). Taken together, these responses
indicate that adolescents find CGMs to be a convenient way to obtain constant data about
their BG levels, and CGM use may aid in metabolic control by helping individuals
identify patterns and opportunities for adjustment.
BG Estimation Accuracy
Error grid analysis based on Parkes and colleagues’ (2000) grid format indicated
that the majority of participants made BG estimations that were inaccurate but without
clinically serious implications. Specifically, if these participants had made adjustment
decisions (e.g., to eat food or dose insulin) based on their estimations, it is likely that
these decisions would not have had serious consequences for affecting BG levels (Parkes
et al., 2000). Adolescents’ estimations were generally more accurate than was expected
based on existing literature showing that up to one-third of adults and children make
clinically serious estimation errors (e.g., Gonder-Frederick, Snyder, & Clarke, 1991).
Lastly, results from this study indicated that participants who reported checking
their BG more frequently per day with a meter made more accurate BG estimations.
Although it was previously postulated that this effect would be found for those using
insulin pumps and CGMs more frequently, the same rationale can instead be applied to
this finding. Insulin pumps and CGMs are heralded for being easy to use and fairly
automatic, and they may take the pressure off of patients to self-monitor their BG levels
and insulin. However, based on the findings from the present study, it seems that the
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more “low-tech,” effortful, less convenient method of BG monitoring is associated with
an increased awareness of one’s current BG level. Because checking one’s BG with a
meter is a minutes-long task that requires individuals to stop what they’re doing and
attend to the number that appears on the screen (instead of glancing quickly at a CGM
reading), it is likely that this task results in increased awareness of how one’s
symptomatology relates to a current BG reading.
Research Implications
The present study is unique within existing research on children and adolescents’
diabetes management in its assessment of immediate, in-the-moment diabetes variables.
Related research has shown impaired cognitive function in adult patients with type 2
diabetes during acute hyperglycemia (Sommerfield, Deary, & Frier, 2004). Additionally,
research examining cognition in children with T1DM has explored the effects of past
severe hyperglycemic or hypoglycemic episodes on subjects’ current cognitive
performance and found impacts of each type of episode on distinct domains of cognitive
function (Perantie et al., 2008). Most closely related to the current research was a study in
which adults with both type 1 and type 2 diabetes completed a cognitive-motor task and
entered current BG levels over a period of four weeks. Results indicated that
hyperglycemia was associated with mild cognitive impairment, although these results
were highly individualized and varied greatly between individuals (Cox et al., 2005). As
discussed previously, an abundance of existing research demonstrates consistently lower
cognitive functioning across domains in children with T1DM compared to their healthy
counterparts (e.g., Brands et al., 2004; Gaudieri et al., 2008; Moheet et al., 2015). Despite
this existing knowledge base, the current study was the first to explore these in-the-
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moment variables in a population of adolescents with T1DM. Notably, the present study
sample demonstrated mean cognitive scores within normal limits based on normative
samples.
Additionally, the naturalistic testing environment sets the present study apart from
most others in its field. The majority of studies examining BG levels in children or adults
with T1DM are conducted in hospital settings. Testing for the current study occurred
during a 10-day overnight camp session; participants were asked to take a brief break
from other camp activities to voluntarily participate. Thus, this research setting mirrored
real-life situations more than the typical hospital setting. For instance, participants were
given the option to pause the testing session after their first BG check to make any
adjustments (i.e., eat food or dose insulin as needed) and wait for those adjustments to
take effect. Although some participants chose to either eat food or dose insulin at this
point, all of them chose to proceed with the testing session without waiting for these
adjustments to take effect. It should be noted that both insulin doses and food
consumption typically do not take effect for about 15 minutes (U.S. Food and Drug
Administration, 2015), so it is unlikely that any adjustments significantly altered
participants’ BG levels for the remainder of the testing session. In this way, the testing
session mirrored adolescents’ daily life, especially in school settings. They often need to
make quick adjustments to their BG values without being able to stop the task at hand
and wait for these adjustments to take effect.
Clinical Implications
Taken together, these results indicate that awareness of subjective physiological
symptomatology is an important aspect of diabetes monitoring. Subjective
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symptomatology is significantly related to certain domains of cognitive function in
adolescents with T1DM, and furthermore, these symptoms are independent from
objective BG values and should thus be considered separately. This finding is especially
relevant in school settings. For example, an adolescent’s objective BG value might be in
range (or close to in range), but the adolescent’s symptomatology might make it difficult
for him or her to perform well. Similarly, because there is no evidence that these
symptoms reliably covary between individuals, two students might have similar BG
values but experience very different symptoms in the moment. It is thus critical that
parents, medical providers, and educators alike acknowledge the role of symptomatology
in affecting adolescents’ functioning and assess symptoms in addition to BG levels in
order to ensure optimum functioning. Additionally, given that there is currently no
standard clinical tool for the assessment of physiological symptomatology in children,
future research should examine the most effective measure of symptomatology that
weighs both the number of symptoms endorsed and the severity of each symptom.
Furthermore, although most adolescents in this sample did not make clinically
serious estimation errors, the majority of participants’ estimates were inaccurate and may
have resulted in altered clinical action (Parkes et al., 2000). This underscores the
importance of encouraging adolescents with T1DM to engage in BG monitoring often,
whether with a meter or a CGM. This is true even when adolescents report feeling “okay”
or “in range;” as demonstrated in these results, adolescents’ subjective evaluations of
their BG levels may not always be accurate.
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Limitations and Future Directions
This study has several limitations that should be acknowledged and considered
when interpreting the results. First, although the naturalistic research setting had many
advantages, one possible disadvantage is that testing at a diabetes camp may have
resulted in a selection bias. As mentioned previously, it is possible that adolescents who
attend diabetes camp may be more motivated to be in a diabetes-positive environment,
meet others with diabetes, and learn new management techniques. As such, participants
in the present study might have been more involved in their diabetes care (and have more
involved families) than the average adolescent; this may limit the generalizability of our
findings to other adolescents with T1DM (Chae, Reith, Tomlinson, Rayns, & Wheeler,
2014; Wang, Stewart, Tuli, & White, 2008).
Second, a significant limitation of this study is that it was not possible to obtain an
objective measure of metabolic control (i.e., HbA1C) from participants given that access to
their medical records was not feasible. Therefore it is not possible to draw any
conclusions about how cognitive performance, subjective symptomatology, technology
use, or BG estimation accuracy relate to metabolic control over a longer period of time. It
was also not feasible to compare the metabolic control of the present study’s participants
to other adolescents with T1DM. Future studies should incorporate a measure of
metabolic control to explore the relation of these variables to longer-term disease
management. Furthermore, management practices outside of technology use were not
assessed and therefore one cannot infer the role that other adherence habits might play.
Diabetes self-management is a complicated and nuanced process, and there are many
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different aspects that may factor into the relationship between treatment adherence and
metabolic control (Hood et al., 2009).
A third limitation to this study is the lack of variation in the type of “out of range”
blood glucose levels participants exhibited (i.e., hyperglycemic or hypoglycemic).
Although many participants had “out of range” BG values at the time of testing, the vast
majority were hyperglycemic; only one was hypoglycemic. Previous research with adults
with T1DM suggests that hyperglycemia is less impairing (cognitively) than
hypoglycemia (Holmes, Hayford, Gonzalez, & Weydert, 1983). Additionally,
hypoglycemia is generally associated with more severe symptoms (Lane, 2006).
Therefore, it is possible that symptomatology and cognitive scores would have been more
variable had some of the participants been hypoglycemic at the time of testing. Unlike in
a medical setting, BG values cannot be manipulated, and any participants who might
begin the study with low BG values are more likely to wait to adjust their values because
of their accompanying severe symptomatology. Future research should thus explore ways
to manipulate participants’ BG values in a similar paradigm or to assess natural
variability over time using CGM data.
Fourth, the symptom inventory used in this study collapsed responses across
symptoms and time points to result in one total symptomatology variable. This scoring
method is imprecise and oversimplified, and it may have resulted in a loss in variation in
symptom reports. Future research on this topic should utilize more precise measures of
symptomatology and consider examining each potential symptom separately instead of
collapsing intensity across many symptoms. Given the idiosyncrasy of symptomatology
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in this population, it would be interesting to examine the relations between individual
symptoms and how rates of endorsement vary among symptoms.
Lastly, although this study utilized global measures of technology, more research
is warranted examining the role of diabetes technology (including meters, insulin pumps,
CGMs, and in the future, closed-loop systems) in disease management. Although many
past studies have examined the metabolic effects of these technologies in children and
adults (Weissberg-Benchell, Antisdel-Lomaglio, & Seshadri, 2003), further research
should specifically investigate which aspects of each technology are most helpful to
children and adolescents with T1DM and how technology use may build (or compromise)
management skills in these populations.
Conclusion
The current study provides new insights into the relationships among blood
glucose levels, subjective symptomatology, and cognitive performance in adolescents
with type 1 diabetes. Adolescents whose blood glucose levels were in range and who
endorsed less symptomatology performed better on certain cognitive assessments than
those whose blood glucose levels were out of range and who endorsed more
symptomatology. Participants who reported looking at the data from their continuous
glucose monitors more frequently were more aware of their symptomatology at the time
of testing. Adolescents who reported checking their blood glucose level more frequently
were more accurate when estimating their blood glucose levels than adolescents who
reported checking less frequently. These results underscore the importance of considering
symptomatology, symptom awareness, and estimation accuracy in school settings in
order to optimize adolescents’ functioning in these settings.
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Table 1.
Error Grid Analysis Zones
Parkes et al. (2000)
Zone A

Errors with no effect on clinical action.

Zone B

Errors resulting in altered clinical action, but little or no effect on
clinical outcome.

Zone C

Errors resulting in altered clinical action; likely to affect clinical
outcome.

Zone D

Errors resulting in altered clinical action; could have significant
medical risk.

Zone E

Errors resulting in altered clinical action; could have dangerous
consequences
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Table 2.
Demographic Characteristics (N = 55)
Mean

SD

Range

n

%

Female

27

49.1

Male

28

50.9

American Indian/Alaska
Native

1

1.8

Asian

1

1.8

Black/African American

2

3.6

White

48

87.2

Multi-racial

2

3.6

Hispanic or Latino

9

16.4

Not Hispanic or Latino

46

83.6

Gender

Age at testing (years)

14.60

1.13

13 - 17

Race

Ethnicity

Age at diagnosis (years)

7.75

3.86

1 - 15

Years attended camp (prior)

3.66

3.23

0 - 12

Median annual income
per zip code

$83,823.23 $27,524.14

$23,363 –
$147,936
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Table 3.
Descriptive Statistics of Outcome Variables (N = 55)
Mean

SD

Range

n

%

109.12

17.70

64.14 151.76

Total Achievement

9.58

2.21

1 - 14

Mean First Move Time

10.42

1.84

4 - 13

Time-Per-Move Ratio

9.56

2.23

2 - 13

Total Symptomatology score*

0.30

0.30

0 - 1.39

Pre-test

191.38

78.44

87 - 417

Post-test

181.30

74.26

67 - 394

In range

19

34.5

Out of range

36

65.5

Zone A

21

38.2

Zone B

33

60.0

Zone C

1

1.8

Zone D

0

0

Zone E

0

0

SDMT Total Standard Score
D-KEFS Tower Standard
Scores

Blood glucose values

Blood glucose range at pre-test

Parkes’ EGA Zones

*Note: Non-transformed group mean values are reported in the table for ease of
interpretation, although transformed values were used as appropriate in analyses.
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Table 4.
Independent Samples T-Test Based on Range of Pre-test Blood Glucose Levels
In range
(n=19)

Out of range
(n=36)

t

Effect size
(Cohen’s d)

114.92
(13.96)

106.05
(18.85)

1.98*

0.53

Total Achievement

10.05 (1.98)

9.33 (2.31)

1.21

0.33

Mean First Move Time

10.36 (1.80)

10.44 (1.89)

-0.15

-0.04

Time-Per-Move Ratio

9.21 (3.12)

9.75 (1.61)

-0.71

-0.22

Total Symptomatology Score

0.57 (0.24)

0.42 (0.28)

2.10*

0.58

SDMT total score
D-KEFS Tower Standard
Score

*p < .05
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Table 5.
Bivariate Correlations Between Cognitive Assessment Scores and Total Symptomatology
1
1. SDMT Total Standard Score

2

3

4

--

2. D-KEFS Tower Total Achievement

-.06

--

3. D-KEFS Tower Mean First Move
Time

.15

.01

--

4. D-KEFS Tower Time-Per-Move Ratio

.01

-.04

.58**

--

5. Total Symptomatology Score

.24

.01

-.31*

-.19

*p < .05, **p < .01
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Table 6.
Central Themes of Helpful CGM Functions
Theme

Percentage of respondents
discussing each theme

Increased awareness of BG levels

56.8

Trend arrows, graphs, data

37.8

Advance notice of BG changes

27.0

Source of information or data

24.3

Convenient

21.6
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Figure 1: Study Procedures
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Parkes (Consensus) Error Grid for Type 1 Diabetes
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Figure 2. Zones of estimation accuracy based on Parkes et al. (2000)’s error grid
analysis. Each data point represents the intersection of a participant’s true BG value (xaxis) and estimated BG value (y-axis).
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Appendix A
Symptom Survey
Which (if any) of the following things are you experiencing right now? Check “yes” or “no”
for each option. For each symptom that you check “yes,” please indicate how severely
you are experiencing the symptom by circling the appropriate number.
Tell me if you don’t know what something means!
1

2

A little bit

3

4

Moderately

5
A lot

Headache

£ Yes

£ No

1

2

3

4

5

Sweating

£ Yes

£ No

1

2

3

4

5

Shakiness

£ Yes

£ No

1

2

3

4

5

Pounding heart

£ Yes

£ No

1

2

3

4

5

Confusion

£ Yes

£ No

1

2

3

4

5

Slurred speech

£ Yes

£ No

1

2

3

4

5

Hunger

£ Yes

£ No

1

2

3

4

5

Thirst

£ Yes

£ No

1

2

3

4

5

Going to the
bathroom a lot

£ Yes

£ No

1

2

3

4

5

Stomachache

£ Yes

£ No

1

2

3

4

5

Blurry vision

£ Yes

£ No

1

2

3

4

5

Feeling tired

£ Yes

£ No

1

2

3

4

5

Feeling weak or
run-down

£ Yes

£ No

1

2

3

4

5

Heavy breathing

£ Yes

£ No

1

2

3

4

5

Nausea

£ Yes

£ No

1

2

3

4

5

Feeling frustrated

£ Yes

£ No

1

2

3

4

5

Feeling irritated

£ Yes

£ No

1

2

3

4

5

Dizzy

£ Yes

£ No

1

2

3

4

5

Tingling or pain in
hands or feet

£ Yes

£ No

1

2

3

4

5

Dry mouth

£ Yes

£ No

1

2

3

4

5

Energetic

£ Yes

£ No

1

2

3

4

5

Sweet taste in
mouth

£ Yes

£ No

1

2

3

4

5

How are you feeling right now?
£ Low
£ In range

£ High

Appendix B
Technology Interview
1.   What technology or devices do you use to take care of your diabetes?
Allow for free response and then follow-up to answer remaining items:

Blood glucose meter

£ Yes How many?_______

Continuous glucose monitor

£

Yes

£

No

Pump

£

Yes

£

No

Injections

£

Yes

£

No

Pens

£

Yes

£

No

Dog

£

Yes

£

No

£

No

2.   On average, how many times a day do you check your blood sugar? _________

3.   If you have a CGM:
a.   How many times a day do you look at your CGM?

b.   How many days in the past month were you on your CGM?

4.   If you have a pump:
a.   How long after your diagnosis did you get your first pump?

b.   Do you ever take pump vacations? (If yes, how often and for how long?)

5.   Do you check your ketones when you’re high?
a.   If yes, how?

£

Yes

£ No
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6.   Does anyone in your family ever look back at your numbers?

£ Yes

£ No

a.   If yes, how often?

b.   If yes, in what way?
£ Yes

£ No

ii.   Downloading number to computer £ Yes

£ No

i.   Scrolling back through meter

iii.   Any other way:____________________________________________
c.   Who looks at the data?
i.   You only

£ Yes

£ No

ii.   You and your parents

£ Yes

£ No

iii.   Parents only

£ Yes

£ No

7.   Do you do anything in particular after you’ve looked at the data?

8.   Does looking at the data change anything about the way you manage your diabetes?

9.   Do you think anything would be different if you didn’t look at the data as often as you
do?

10.  Do you use any apps to track or manage your diabetes?
a.   If yes, which one(s)?
b.   If yes, how often do you use the app?

11.  Is there anything else you want to tell us about how you use technology to monitor
your diabetes?

